Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

Clinical trial NCT07247383 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07247383
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Marginal Zone Lymphoma of Ocular Adnexal Marginal Zone Lymphoma(MZL)

Start date: 2025-09-19
Primary completion: 2027-12-31
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.